API | lesogaberan

lesogaberan Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Lesogaberan (AZD-3355) was an experimental drug candidate developed by AstraZeneca for the treatment of gastroesophageal reflux disease (GERD). As a GABAB receptor agonist, it has the same mechanism of action as baclofen, but is anticipated to have fewer of the central nervous system side effects that limit the clinical use of baclofen for the treatment of GERD. ^Wikipedia

Chemistry

SMILES: NC[C@@H](F)CP(=O)O
InChIKey: LJNUIEQATDYXJH-GSVOUGTGSA-N
Mol. Mass: 141.08
ALogP: -0.25 Partition coefficient
ChEMBL Molecule:
lesogaberan

More Chemistry

Pharmacology

Mechanisms of Action:
- Gamma-aminobutyric acid type B receptor subunit 1 (Homo sapiens) ^UniProt
- Gamma-aminobutyric acid type B receptor subunit 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

azd3355 | azd 3355 | azd-3355 | lesogaberan

Organizations (8)

Research & Development (8)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Bile Reflux (Phase 2)

Gastroesophageal Reflux (Phase 2)

Heartburn (Phase 2)

Renal Elimination (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 10
# of Trial Organizations: 8

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue